A Systematic Review and Meta-Analysis of the Prognostic Value of Tumor Response Measurements During Radiotherapy for Head and Neck cancers.

Clin Oncol (R Coll Radiol)Aug 1, 2026 (epub)
Clinical ResearchRadiology (Diagnostic)Oncology (Medical)

S H Poulsen, R Jørgensen, I Vogelius et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of in-treatment tumor response measurements during radiotherapy for head and neck cancer, analyzing 98 studies. It found that a low tumor volume reduction rate on CT was associated with poorer loco-regional control (HR: 4.6), while high SUVmax on FDG-PET indicated poorer overall survival (HR: 1.97) and loco-regional control (HR: 1.72).

Key findings

  • Low tumor volume reduction rate on CT was associated with poorer loco-regional control (HR: 4.6).
  • High SUVmax on FDG-PET was a significant prognostic marker for poorer overall survival (HR: 1.97).
  • High SUVmax on FDG-PET also indicated poorer loco-regional control (HR: 1.72).
  • Changes in ADC on MRI showed no significant prognostic value for loco-regional control (HR: 0.97).

Why it matters

Understanding the prognostic value of imaging modalities during treatment can help clinicians better assess treatment responses and tailor management strategies for patients with head and neck cancer.

What to keep in mind

Only 19.4% of studies could be included in the meta-analyses due to missing data.

Source

PubMed · PMID 42623777

Published in Clin Oncol (R Coll Radiol). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.